Research use only · Multi-region fulfillment · Support-assisted ordering
VestaResearch Supply
Jalra M 50/500mg Tablets | 105-Count | VILDAGLIPTIN
PharmaWeight Loss & Metabolic

Jalra M 50/500mg Tablets | 105-Count | VILDAGLIPTIN

$130

In stock

For in vitro laboratory research only. Not for human or veterinary consumption.

India Warehouse VILDAGLIPTIN — 500mg per tablet, 105-count pack. DPP-4 inhibitor for type 2 diabetes. Twice daily dosing. Widely used in Europe and Asia as monotherapy or combined with metformin, sulfonylureas, or insulin. Key warning: Liver function monitoring required (quarterly for first year). Pancreatitis — discontinue if suspected. Avoid if eGFR under 50. Severe joint pain may be delayed onset class effect.

SKU
VES-005452-JALRA-500MG-105TAB
Format
N/A
Use
Laboratory research only
Ask on Telegram

What is Jalra M 50/500mg (VILDAGLIPTIN)?

DPP-4 inhibitor for type 2 diabetes. Twice daily dosing. Widely used in Europe and Asia as monotherapy or combined with metformin, sulfonylureas, or insulin.

How it Works

Inhibits DPP-4, preventing degradation of GLP-1 and GIP incretin hormones — increases insulin secretion and decreases glucagon in glucose-dependent manner. No hypoglycemia as monotherapy.

Quick Specs

Form
Oral tablets — pre-dosed
Active Ingredient
VILDAGLIPTIN
Dose per Tablet
500MG
Pack Size
105 tablets
Storage
Room temperature (15–25°C), cool dry place
Shelf Life
2–3 years (properly stored)

Common Side Effects

Nasopharyngitis, headache, dizziness, peripheral edema, liver enzyme elevation. Rare: pancreatitis, severe joint pain.

Safety Warnings

Liver function monitoring required (quarterly for first year). Pancreatitis — discontinue if suspected. Avoid if eGFR under 50. Severe joint pain may be delayed onset class effect. International shipping: 7–14 days

Research use only

This material is supplied strictly for in vitro laboratory research. It is not intended for human or veterinary consumption, diagnosis, treatment, or household use.